Advanced Monitoring to Inform and Guide Perioperative Hemodynamic Optimization 1 (AMIGO-1) Study
AMIGO-1
A Single Centre Feasibility Randomized Controlled Trial of Advanced Minimally Invasive Monitoring to Optimize Hemodynamic Management in Major Noncardiac Surgery
1 other identifier
interventional
60
1 country
1
Brief Summary
Serious complications occur in about 16% of major surgeries. Episode of hypotension during surgery may be a leading cause of these complications. Even though hypotension occurs frequently during surgery, choosing the correct treatment remains difficult in clinical practice. Physicians are often uncertain as to whether low blood pressure should be treated with intravenous fluid or vasoactive drugs. The first treatment of choice typically involves administering more intravenous fluid; however, excessive fluid administration during surgery has been shown to be deleterious. New minimally invasive hemodynamic monitors now offer a potential solution by guiding physicians with respect to the choice of appropriate intervention (i.e., fluid versus vasoactive drugs). The Investigators will conduct a single-center feasibility randomized control trial (RCT) at the Toronto General Hospital (Toronto, ON, Canada) of an algorithm to manage hypotension during surgery based on the information captured by a minimally invasive monitor. Sixty participants who are aged 40 years or older and scheduled to undergo an abdominal, pelvic or vascular surgery will be randomized to have the intraoperative hypotension managed by either the new algorithm (guided by the monitor) or usual care. Participants will be recruited over 12 to 18 months, and followed for 30 days to describe differences in clinical care, hemodynamics, complications, and death. The feasibility of a future multicenter RCT will be assessed based on this present study demonstrating that (1) the algorithm can be practically implemented in a clinical setting where hemodynamic monitors are not typically used; (2) initial descriptive data suggest differences in care between groups; (3) there are no obvious major harms from the protocol; and (4) there is an acceptable participation rate among eligible patients. These data will inform any required changes to the algorithm and protocol to allow for its application in a future study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 26, 2018
CompletedFirst Posted
Study publicly available on registry
March 26, 2018
CompletedStudy Start
First participant enrolled
May 3, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2019
CompletedSeptember 29, 2020
September 1, 2020
1.3 years
February 26, 2018
September 28, 2020
Conditions
Outcome Measures
Primary Outcomes (3)
Survey score on practicality of study algorithm (Intervention)
• Practicality of study algorithm will be measured by the survey scores of the anesthesiologists involved in the intraoperative care, assessing several domains using a 5 point Likert scale such as (1) Ease of use, (2) Clinical Utility, (3) Validity
2 years
Participation rate (Feasibility trial pre-RCT)
• Participation rate: The number of patients consented to the study over the number of eligible patients. This will help estimate recruitment rates in a future clinical randomized trial.
2 years
Incidence of treatment related Adverse Events
Number of participants with Adverse Events thought to be at least possibly related to the study treatment will be reported. This outcome will assure that no harm has resulted from the study protocol and the protocol is safe for a future randomized control trial
2 years
Secondary Outcomes (3)
Volume of intravenous fluid and volume of blood products (therapeutic interventions) for each arm of the study.
During intra-operative period and recovery, an average of 12 hours.
Dose of vasoactive medication (therapeutic interventions) for each arm of the study.
During intra-operative period and recovery, an average of 12 hours.
Hypotension (blood pressure in mmHg) (therapeutic interventions) for each arm of the study
During intra-operative period and up to 72 hours after surgery.
Study Arms (2)
Intraoperative Hemodynamic Algorithm
EXPERIMENTALIn the experimental group, the anesthesiologist will have complete access to data from the minimal invasive cardiac output monitor. During the intraoperative period, the anesthesiologist will be instructed to use a hemodynamic management algorithm to manage episodes of significant hypotension
Usual Hemodynamic Management
ACTIVE COMPARATORIn the control arm, the participant will be monitored by the cardiac output monitor, but the anesthesiologists in the operating room will be blinded to hemodynamic data from the monitor. Data from the monitor will be stored electronically and used to compare hemodynamic parameters between study arms.
Interventions
Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
Eligibility Criteria
You may qualify if:
- Age ≥40 years
- Abdominal, retroperitoneal, pelvic or vascular surgery requiring general anesthesia and planned postoperative stay of ≥48 hours for medical reasons
- Elevated perioperative cardiovascular risk based on at least one of the following:
- cardiovascular comorbidities: coronary artery disease, heart failure, cerebrovascular disease, or peripheral arterial disease
- elevated age (≥70 y),
- smoker,
- hypertension,
- diabetes mellitus,
- or preoperative estimated glomerular filtration rate ≤60mL/min/1.73m2
- Planned placement of invasive arterial line for clinical care
You may not qualify if:
- Preoperative dialysis dependence
- Minimally invasive procedures (i.e., laparoscopic or endovascular approach)
- Intra-thoracic procedures
- Non-sinus rhythm
- Liver resection surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Toronto General Hospital, University Health Network
Toronto, Ontario, M5G 2C4, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Duminda N Wijeysundera, Dr
Universtiy Health Network. Toronto General Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 26, 2018
First Posted
March 26, 2018
Study Start
May 3, 2018
Primary Completion
September 1, 2019
Study Completion
September 1, 2019
Last Updated
September 29, 2020
Record last verified: 2020-09